BIOLOGÍA MOLECULAR Y CELULAR EN HEMOPATÍAS
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario Virgen del Rocío (40)
2024
-
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
Cancer, Vol. 130, Núm. 20, pp. 3436-3451
2023
-
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Blood Advances, Vol. 7, Núm. 1, pp. 167-173
-
Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study
Cancers, Vol. 15, Núm. 5
-
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia
British Journal of Haematology
2022
2021
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma
Blood, Vol. 137, Núm. 1, pp. 49-60
-
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
Leukemia, Vol. 35, Núm. 6, pp. 1571-1585
-
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Leukemia, Vol. 35, Núm. 8, pp. 2358-2370
-
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
Scientific Reports, Vol. 11, Núm. 1
-
The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial
Cancers, Vol. 13, Núm. 10
2020
-
Corrigendum to “Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study” [Leuk. Res. 92 (March) (2020) 06352] (Leukemia Research (2020) 92, (S0145212620300576), (10.1016/j.leukres.2020.106352))
Leukemia Research
-
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792
-
Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study
Leukemia Research, Vol. 92
2019
-
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients
Leukemia Research, Vol. 76, pp. 1-10
-
Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population
British Journal of Haematology, Vol. 185, Núm. 3, pp. 480-491
2018
-
A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
Annals of Hematology, Vol. 97, Núm. 5, pp. 763-772
-
Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy
Modern Pathology, Vol. 31, Núm. 8, pp. 1318-1331
-
Correction to: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia (Annals of Hematology, (2018), 10.1007/s00277-018-3229-5)
Annals of Hematology
2016
-
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis
Blood, Vol. 127, Núm. 9, pp. 1151-1162
-
Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations
Oncotarget, Vol. 7, Núm. 49, pp. 80916-80924